Skip to main content
. 2019 Nov 20;25(3):e469–e476. doi: 10.1634/theoncologist.2019-0541

Table 2.

Cox proportional hazard analysis of the risk of overall survival in patients with metastatic colorectal cancer receiving TAS‐102

Factor HR (95% CI) p value
Combination with bevacizumab 0.30 (0.14–0.66) .003
Age (IQR: 56–72) 1.41 (0.88–2.25) .151
Modified Glasgow prognostic score 1.87 (0.86–4.05) .113

graphic file with name ONCO-25-e469-g005.jpg

Abbreviations: CI, confidence interval; HR, hazard ratio; IQR, interquartile range.